Sumitomo Pharma America
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sumitomo Pharma America sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Sumitomo Pharma America: 168 sponsored US clinical trials, 6 recruiting.
Sumitomo Pharma America sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 142 completed. 83 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 4 trials.
Top-decile sponsor footprint
Sumitomo Pharma America ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 3 of 4
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
NCT01067105
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
NCT01033825
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
NCT01010971
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
NCT01042106
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
NCT00953147
Eslicarbazepine Acetate Monotherapy Long Term Study
NCT00910247
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT00909779
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
NCT00857220
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
NCT01074632
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
NCT00856973
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
NCT00868452
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
NCT00866775
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
NCT00868699
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
NCT00868959
A Study of BBI608 in Adult Patients With Advanced Malignancies
NCT01775423
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
NCT00789698
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
NCT00809757
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
NCT00790023
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCT00790192
Midazolam Drug-Drug Interaction Study With Lurasidone HCl
NCT01082263
Digoxin Drug-Drug Interaction With Lurasidone HCl
NCT01082289
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
NCT01082146
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
NCT01082276
Lithium Drug-Drug Interaction Study With Lurasidone HCl
NCT01074073
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
NCT01082250
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
NCT00641745
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCT00615433
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
NCT00616655
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
NCT00583947
A Safety, Efficacy and Tolerability Study of SEP-225289
NCT00584974
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
NCT00571428
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
NCT00549718
A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
NCT00549666
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
NCT00409539
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00424528
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
NCT00386334
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
NCT00359944
Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB
NCT00268723
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
NCT00250679
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
NCT00583986
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
NCT00235508
Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
NCT00685529
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
NCT00088621
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
NCT00088634
Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause
NCT00366093
Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
NCT00367965
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
NCT00368030
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
NCT00352144
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00691405
Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)
NCT00685269
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 27 |
| Phase 3 | 75 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Sumitomo Pharma America pipeline
6 recruiting of 168 indexed (4% open); 142 completed (85%).
Phase mix: 83 late (III/IV) vs 80 early (I/II) (balanced across stages).
Top condition: Schizophrenia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sumitomo Pharma America: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Sumitomo Pharma America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Sumitomo Pharma America page
168 registered trials is a research-attention snapshot, not an endorsement of Sumitomo Pharma America or any single study.
- 6 of Sumitomo Pharma America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Sumitomo Pharma America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sumitomo Pharma America pipeline card: 168 registered trials from official public datasets.Report a data error.